Arrowhead’s Redemplo secures Australian TGA approval for FCS therapy
Arrowhead Pharmaceuticals has received approval from the Australian Therapeutic Goods Administration (TGA) for Redemplo (plozasiran) to treat familial chylomicronemia syndrome …
Post
-
-
Novo Nordisk to launch Ozempic for type 2 diabetes in US
Novo Nordisk is set to launch Ozempic, its oral glucagon-like peptide-1 (GLP-1) receptor agonist pill for adults with type 2 …
-
The cost of inefficiencies in clinical trials
Clinical trials are expensive, time-sensitive, and closely monitored, with sponsors and contract research organisations (CROs) under pressure to run studies …
-
How Saudi Arabia is developing as a Middle East hub for clinical trials
Saudi Arabia is primed to emerge as the Middle East’s key hub for clinical trials, driven by both sustained state …
-
Axsome receives FDA approval for Auvelity to treat Alzheimer’s agitation
Axsome Therapeutics has received the US Food and Drug Administration (FDA) approval for Auvelity (dextromethorphan HBr and bupropion HCl) to …
-
Novo Nordisk to launch Ozempic for type 2 diabetes in US
Novo Nordisk is set to launch Ozempic, its oral glucagon-like peptide-1 (GLP-1) receptor agonist pill for adults with type 2 …
-
The cost of inefficiencies in clinical trials
Clinical trials are expensive, time-sensitive, and closely monitored, with sponsors and contract research organisations (CROs) under pressure to run studies …
-
How Saudi Arabia is developing as a Middle East hub for clinical trials
Saudi Arabia is primed to emerge as the Middle East’s key hub for clinical trials, driven by both sustained state …
-
Axsome receives FDA approval for Auvelity to treat Alzheimer’s agitation
Axsome Therapeutics has received the US Food and Drug Administration (FDA) approval for Auvelity (dextromethorphan HBr and bupropion HCl) to …
-
Eli Lilly lifts 2026 revenue guidance as Q1 marks dominant opening
Buoyed by yet another strong quarter fuelled by obesity drug demand, Eli Lilly has raised its sales expectations for the …
-
BMS brings the buzz around late-stage readouts amid a so-so Q1
The prospect of upcoming pivotal readouts from Bristol Myers Squibb (BMS) has brought a buzz amongst investors, as the company …
-
LEO Pharma to acquire gene therapy company Replay
LEO Pharma has signed a definitive agreement for the acquisition of Replay, a gene therapy company that develops treatments for …
-
Thinning revenues: inside the $14bn Eliquis patent cliff
Eliquis (apixaban) is one of the most commercially consequential loss-of-exclusivity (LOE) events in recent pharmaceutical history, with patent expiries expected …
-
Chiesi widens rare disease portfolio with $1.9bn KalVista buyout
Chiesi has conducted the largest acquisition in its 90-year history, agreeing to buy KalVista Pharmaceuticals in a deal worth around …
-
Teva signs off $900m Emalex buyout amid strategic pipeline boosting ploy
Teva Pharmaceuticals will acquire neuroscience specialist, Emalex – a move which Teva executive, Evan Lippman, says effectively complements the company’s …
